Cullinan Therapeutics (CGEM) announced that the FDA has granted orphan drug designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute myeloid leukemia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
- Cullinan Therapeutics price target raised to $37 from $36 at Wedbush
- Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)
- Cullinan jumps after UCB acquires Candid Therapeutics
- Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook